



Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022

- Presentations Showcase Eiger's Innovative Therapies for Hepatitis Delta Virus

Palo Alto, Calif., June 8, 2022 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced four abstracts to be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom.

Oral presentation:

Title: Lonafarnib Combination with Peginterferon Lambda Diminished Triphasic HDV Kinetic Pattern Seen Under Lambda Monotherapy: the *LIFT-1* HDV Study

Authors: Duehren, S.; Heller, T. et al.

Session: Hepatitis B Emerging Therapies

Date & Time: June 25, 8:30 a.m. - 8:45 a.m. British Summer Time (BST)

Abstract #: 1904

Presenter: Harel Dahari

Poster presentations:

Title: Strong Correlation Between HBsAg, ALT and HDV-RNA Levels in Patients with Chronic Hepatitis Delta: Results of Phase 3 *D-LIVR* Study

Authors: Buti, M.; Lampertico, P. et al.

Session: Viral Hepatitis A, B, C, D, E: Virology

Date & Time: June 23, 9:00 a.m. - 6:30 p.m. BST

Abstract #: 3494

Title: Clinical Features Predictive of Cirrhosis in a Large Cohort of Patients with Chronic Hepatitis Delta Infection - Insights from the *D-LIVR* Trial

Authors: Etzion, O.; Lampertico, P. et al.

Session: Viral Hepatitis B/D: Clinical Aspects Except Therapy

Date & Time: June 23, 9:00 a.m. - 6:30 p.m. BST

Abstract #: 3442

Title: Mathematical Modeling of HDV RNA Kinetics Suggests High Peginterferon Lambda Efficacies in Blocking Viral Production and Infection: Insights from the *LIMIT-1* Study

Authors: Cardozo-Ojeda, E.F.; Etzion, O. et al

Session: Viral Hepatitis B/D: Therapy

Date & Time: June 25, 9:00 a.m. - 6:00 p.m. BST

Abstract #: 2072

Additional Congress Activities:

Event: 21st Hepatitis Delta International Network

Presentation Title: Lonafarnib and Peginterferon Lambda: Monotherapy and Combination Treatments in Late-Stage Development for HDV

Date & Time: June 22, 4:00 p.m. BST

Location: ExCel London, South Gallery 27

Presenter: Ingrid Choong, Ph.D., SVP, Clinical Development Eiger BioPharmaceuticals

Event: Eiger Booth #101

Date & Time: June 23-25, 9:00 a.m. - 5:00 p.m. BST

Event: Eiger Reception for Investigators, Investors and Analysts

Date: June 23, 5:30 - 7:00 p.m. BST

Location: Prince Regent #3

ENDS

About Eiger

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and reported positive results from *TOGETHER*, a Phase 3 investigator-initiated study.

All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Contacts

Investors:

Sylvia Wheeler

Wheelhouse Life Science Advisors

swheeler@wheelhousesa.com

Media:

Sarah Mathieson

SVP, Corporate Affairs

smathieson@eigerbio.com